Exome Invests in Impact Therapeutics’ Series D1 Financing

NEW YORK–(BUSINESS WIRE)–Exome Asset Management LLC, led by Sam Isaly, participated in the Series D1 financing of IMPACT Therapeutics, a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, which recently closed. Proceeds will be used to accelerate the development of its synthetic lethality programs, many of which are showing best-in-class potential.

“Synthetic lethality is one of several promising new approaches to the treatment of cancers. Exome is excited to contribute to the development of targeted therapeutics to contribute to the well-being of mankind”, asserted Mr. Isaly.

IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. In 2021, IMPACT achieved breakthroughs on multiple targets including PARP, Wee1, and ATR, becoming one of the biotech companies with the broadest DDR pipelines in the world and is expanding to other novel synthetic lethality targets to broaden its pipelines. Today, the company already has three synthetic lethality compounds in the clinical stage.

Dr. Jun Bao, President and CEO of IMPACT Therapeutics said: “We thank these excellent investment institutions for their support and trust in IMPACT. The successful closing gave us more confidence to implement our global development strategy and advance various clinical trials at full speed. We look forward to working with clinical investigators and other partners to bring more efficacious therapies to patients around the world.”

About IMPACT Therapeutics

IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage response (DDR) global pipelines of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/ IMP4297), Wee1 inhibitor (IMP7068), ATR inhibitor (IMP9064) and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China. Senaparib’s preliminary clinical data demonstrated superior tolerability and wider therapeutic windows compared with other PARPi. Phase I study of Wee1 inhibitor (IMP7068) is conducted globally. Phase 1 study of ATR Inhibitor is also undergoing in several countries. Hedgehog pathway inhibitor (IMP5471) has received IND approval from NMPA to initiate clinical studies in China. For more information, please visit www.impacttherapeutics.com/en/.

About Exome Asset Management

Exome Asset Management is an innovative asset management company focusing on investing in public markets across the worldwide healthcare industry, including pharmaceuticals, biotechnology, healthcare services, and medical devices. Exome employs sound investment strategies and a philosophy developed by Sam Isaly, who has spent the majority of his 45-year career focused on both developed and emerging markets healthcare. For more information, please visit www.exomeasset.com

Contacts

Alex Forschner

Head of Business Development

(212) 403-3907

[email protected]